Gemigliptin

Drug Profile

Gemigliptin

Alternative Names: Gemigliptin tartrate sesquihydrate; Gemiglo®; LC-150444; Zemiglo

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LG Life Sciences
  • Developer LG Chem; Sanofi
  • Class Antihyperglycaemics; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II/III Acute kidney injury

Most Recent Events

  • 12 Sep 2017 Phase-II/III development for Acute kidney injury (In adults, In the elderly, Prevention) is ongoing in South Korea (PO) (NCT02250872)
  • 12 Sep 2017 No recent reports on development identified - Phase-III for Type-2 diabetes mellitus (Adjunctive treatment) in USA and Russia (PO)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top